

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>NATIXIS PRIVATE EQUITY</u>	2. Date of Event Requiring Statement (Month/Day/Year) <u>02/12/2015</u>	3. Issuer Name and Ticker or Trading Symbol <u>EYEGATE PHARMACEUTICALS INC [EYEG]</u>
(Last) (First) (Middle) <u>5-7 RUE DE MONTESSUY</u>		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
(Street) <u>PARIS IO 75007</u>		5. If Amendment, Date of Original Filed (Month/Day/Year)
(City) (State) (Zip)		6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned			
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)							
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series D Preferred Stock	(1)	(1)	Common Stock	576,564	(2)	I	See Footnote ⁽³⁾
Common Stock Warrants (right to buy)	01/01/2015	06/06/2019	Common Stock	63,442	(4)	I	See Footnote ⁽³⁾

Explanation of Responses:

1. The Issuer's Preferred Stock is convertible into Common Stock at any time at the holder's election. There is no expiration date for any series of Preferred Stock.
2. All outstanding shares of the Issuer's Series D Preferred Stock will automatically convert on a 10.96-for-one basis into Common Stock as shown in column 3 immediately upon the closing of the Issuer's initial public offering, for no additional consideration.
3. Represents shares and warrants held by NPE Coinvest ("NC"). Natixis Private Equity ("NPE") owns 100% of NC. NPE disclaims beneficial ownership of these securities and this report shall not be deemed an admission that NPE is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of its pecuniary interest therein. Voting and investment power over the shares held by NC may be deemed to be shared with NPE due to its parent relationship. Each of Dominique Sabassier ("Sabassier") and Cyrille Marcilhacy ("Marcilhacy ") are officers of NPE. Each of Sabassier and Marcilhacy disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein.
4. The per-share exercise price will be equal to the price per share at which shares of Common Stock are sold to the public pursuant to the Company's initial public offering.

Remarks:

*Signed under power of attorney on behalf of Reporting Person

/s/ Authorized Signatory* 02/12/2015
** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.